P. Van Remoortere

2.1k citations

74 papers · 1.6k indexed · h-index 19

Co-authors: P. Joos Marcus E. Brewster Jef Peeters J.P. Tollenaere Marianne Stowell Bracke Gerben van ‘t Klooster Piet Wigerinck Lieven Baert
Topics: Hepatitis C virus research (15 papers)HIV/AIDS drug development and treatment (9 papers)Liver Disease Diagnosis and Treatment (9 papers)
Cited by: Pharmaceutical Science Hepatology Virology
Journals: The Journal of Chemical Physics Gastroenterology Journal of Colloid and Interface Science
Partner nations: Belgium United States New Zealand

In The Last Decade

P. Van Remoortere

71 papers receiving 1.5k citations

Peers

Countries citing papers authored by P. Van Remoortere

Since Specialization

Citations

This map shows the geographic impact of P. Van Remoortere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Van Remoortere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Van Remoortere more than expected).

Fields of papers citing papers by P. Van Remoortere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Van Remoortere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Van Remoortere. The network helps show where P. Van Remoortere may publish in the future.

Co-authorship network of co-authors of P. Van Remoortere

This figure shows the co-authorship network connecting the top 25 collaborators of P. Van Remoortere. A scholar is included among the top collaborators of P. Van Remoortere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Van Remoortere. P. Van Remoortere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults 2023 ·Antiviral Therapy ·Wim Pierson,Marianne Tuefferd,Florence Herschke,Leen Slaets,Marjolein Crabbe,(unknown),(unknown),Ian Strickland,Edward Gane,Christian Schwabe,Yingjie Zhang,Peter Meerts,Joris Vandenbossche,P. Van Remoortere,(unknown),An De Creus	0
2	Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants 2023 ·Antiviral Therapy ·(unknown),Yue Hu,Edward Gane,Leen Slaets,An De Creus,(unknown),Junqi Niu,Christian Schwabe,Nele Goeyvaerts,(unknown),(unknown),Marianne Tuefferd,(unknown),P. Van Remoortere,Ullrich Schwertschlag,Joris Vandenbossche	2
3	Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study 2020 ·Health Science Reports ·Eric Lawitz,Fred Poordad,Julio Gutiérrez,Maria Beumont,Greet Beets,(unknown),P. Van Remoortere,Donghan Luo,Leen Vijgen,Veerle Van Eygen,Mohamed Gamil	5
4	Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen 2017 ·Antimicrobial Agents and Chemotherapy ·Stefan Bourgeois,Yves Horsmans,Frederik Nevens,Hans Van Vlierberghe,Christophe Moreno,Maria Beumont,Leen Vijgen,Veerle Van Eygen,Donghan Luo,(unknown),P. Van Remoortere,(unknown),Sivi Ouwerkerk‐Mahadevan	6
5	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection 2017 ·BMC Gastroenterology ·Stefan Bourgeois,Hans Van Vlierberghe,Christophe Moreno,Hans Orlent,Frederik Nevens,Keikawus Arastéh,Yves Horsmans,Jörn M. Schattenberg,Peter Buggisch,Sven Francque,Leen Vijgen,Thomas N. Kakuda,(unknown),Donghan Luo,An Vandebosch,(unknown),P. Van Remoortere,René Verloes	4
6	Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model 2010 ·European Respiratory Journal ·Wieslawa Olszewska,Gabriela Ispas,Corinna Schnoeller,(unknown),Tom Van de Casteele,David Nauwelaers,(unknown),Dirk Roymans,Marc De Meulder,M.C. Rouan,P. Van Remoortere,Jean‐François Bonfanti,(unknown),A. Koul,(unknown),Koen Andries,(unknown),Belinda Wang,Peter Openshaw,René Verloes	42
7	Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs 2010 ·European Journal of Pharmaceutical Sciences ·Elke Van Gyseghem,Lieven Baert,P. Van Remoortere,Gerben van ‘t Klooster,M.C. Rouan,Jody Voorspoels,Herman de Kock,Laurent Schueller,Jan Rosier,(unknown),Guy Van den Mooter	6
8	Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients 2009 ·Gastroenterology ·H. W. Reesink,Gregory Fanning,(unknown),Christine J. Weegink,André van Vliet,Gerben van ‘t Klooster,Oliver Lenz,(unknown),(unknown),P. Van Remoortere,Herman de Kock,F. Broeckaert,Paul Meyvisch,(unknown),Kenneth Simmen,René Verloes	123
9	Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment 2009 ·European Journal of Pharmaceutics and Biopharmaceutics ·Lieven Baert,Gerben van ‘t Klooster,(unknown),(unknown),(unknown),(unknown),Koen Iterbeke,(unknown),Paul Stevens,Laurent Schueller,P. Van Remoortere,Guenter Kraus,Piet Wigerinck,Jan Rosier	185
10	855 ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER 2008 ·Journal of Hepatology ·(unknown),(unknown),(unknown),(unknown),Marieke Voets,Jos Van Houdt,René Verloes,(unknown),(unknown),P. Van Remoortere,F. Broeckaert,Herman de Kock,Kenneth Simmen	3
11	Powder for reconstitution of the anti-HIV-1 drug TMC278 – Formulation development, stability and animal studies 2008 ·European Journal of Pharmaceutics and Biopharmaceutics ·Elke Van Gyseghem,(unknown),Lieven Baert,Jan Rosier,Gerben van ‘t Klooster,(unknown),Marie‐Paule Bouche,Laurent Schueller,P. Van Remoortere,Piet Wigerinck,Erwin Adams,Jos Hoogmartens,Guy Van den Mooter	15
12	Development of an implantable infusion pump for sustained anti-HIV drug administration 2008 ·International Journal of Pharmaceutics ·Lieven Baert,Laurent Schueller,Y. Tardy,(unknown),(unknown),Herman Borghys,(unknown),Guy Van den Mooter,Elke Van Gyseghem,P. Van Remoortere	14
13	64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY 2008 ·Journal of Hepatology ·Hendrik W. Reesink,René Verloes,(unknown),(unknown),Christine J. Weegink,Gerben van ‘t Klooster,(unknown),(unknown),P. Van Remoortere,Herman de Kock,F. Broeckaert,Gregory Fanning,Paul Meyvisch,(unknown),Kenneth Simmen	16
14	Dog model with implanted pump to test boosters for antiretroviral medication 2007 ·International Journal of Pharmaceutics ·Laurent Schueller,Lieven Baert,Sophie Lachau‐Durand,Herman Borghys,(unknown),Guy Van den Mooter,Elke Van Gyseghem,Tim H. M. Jonckers,P. Van Remoortere,Piet Wigerinck	2
15	5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Patrick Angibaud,(unknown),Ann Devine,David W. End,Eddy Freyne,(unknown),Philippe Müller,Geert Mannens,(unknown),(unknown),(unknown),G. Smets,Jacky Van Dun,P. Van Remoortere,Marc Venet,Walter Wouters	27
16	Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Patrick Angibaud,(unknown),David W. End,Eddy Freyne,Michel Janicot,(unknown),(unknown),Geert Mannens,(unknown),Laurence Mévellec,Christophe Meyer,Philippe Müller,(unknown),(unknown),Bruno Roux,G. Smets,Jacky Van Dun,P. Van Remoortere,Marc Venet,Walter Wouters	19
17	Characterization of the interaction of 2‐hydroxypropyl‐β‐cyclodextrin with itraconazole at pH 2, 4, and 7 2002 ·Journal of Pharmaceutical Sciences ·Jef Peeters,(unknown),J.P. Tollenaere,P. Van Remoortere,Marcus E. Brewster	241
18	Introduction of Simulation and SLAM 1979 ·Mathematics and Computers in Simulation ·P. Van Remoortere	30
19	Locally interacting systems and their application in Biology. Proceedings of the School-Seminar on Markov interaction processes in biology, held in Pushchino, Moscow in March 1976 1979 ·Mathematics and Computers in Simulation ·P. Van Remoortere	1
20	Software Engineering 1979 ·Mathematics and Computers in Simulation ·P. Van Remoortere	1

About P. Van Remoortere

P. Van Remoortere is a scholar working on Hepatology, Hardware and Architecture and Infectious Diseases, having authored 74 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (9 papers) and Liver Disease Diagnosis and Treatment (9 papers). The work is most often cited by research in Pharmaceutical Science (272 citations), Hepatology (237 citations) and Virology (97 citations). P. Van Remoortere has collaborated with scholars based in Belgium, United States and New Zealand. Frequent co-authors include P. Joos, Marcus E. Brewster, Jef Peeters, J.P. Tollenaere, Marianne Stowell Bracke, Gerben van ‘t Klooster, Piet Wigerinck, Lieven Baert, Laurent Schueller and Jan Rosier. Their work appears in journals such as The Journal of Chemical Physics, Gastroenterology and Journal of Colloid and Interface Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact